Increased risk for hepatitis C associated with solvent use among Canadian Aboriginal injection drug users

Harm Reduction Journal

Volumn 7, Issue , 2010, Pages

  Shaw, Souradet Y ^a   Deering, Kathleen N ^b   Jolly, Ann M ^c,d   Wylie, John L ^a,e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e CADHAM PROVINCIAL LABORATORY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; COCAINE; DIAMORPHINE; HYDROMORPHONE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MORPHINE; OXYCODONE; PENTAZOCINE; SOLVENT;

ABORIGINE; ADOLESCENT; ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; FEMALE; HEPATITIS C; HUMAN; MALE; PREVALENCE; RISK ASSESSMENT; SELF REPORT;

EID: 77954667312     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-7-16     Document Type: Article

References (71)

1. Centers for Disease Control and Prevention HIV/AIDS Surveillance Report. 2007, Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Disease Control and Prevention.
2. Frohlich KL, Ross N, Richmond C. Health disparities in Canada today: Some evidence and a theoretical framework. Health Policy 2006, 79(2-3):132-43. 10.1016/j.healthpol.2005.12.010, 16519957.
3. O'Neil JD, Reading J, Leader A. Changing the relations of surveillance: the development of a discourse of resistance in Aboriginal epidemiology. Hum Organ 1998, 57:230-7.
4. Public Health Agency of Canada HIV/AIDS Epi Notes: Understanding the HIV/AIDS epidemic among Aboriginal Peoples in Canada: the community at a glance. 2004, Public Health Agency of Canada, Public Health Agency of Canada.
5. Wright MR, Giele CM, Dance PR, et al. Fulfilling prophecy? Sexually transmitted infections and HIV in Indigenous people in Western Australia. eMJA 2005, 183:124-8.
6. Centers for Disease Control and Prevention Sexually Transmitted Disease Surveillance. 2008, Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Disease Control and Prevention.
7. Craib KJP, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 2003, 168:19-24. 139313, 12515780.
8. Miller C, Strathdee S, Spittal P, et al. Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting. Harm Reduct J 2006, 3(1):9. 10.1186/1477-7517-3-9, 1431516, 16524484.
9. Wood E, Montaner JSG, Li K, et al. Burden of HIV infection among Aboriginal injection drug users in Vancouver, British Columbia. Am J Public Health 2008, 98:515-9. 10.2105/AJPH.2007.114595, 2253561, 18235063.
10. DeBeck K, Kerr T, Fischer B, et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ 2009, 181:585-9. 2764753, 19841052.
11. Manitoba Health and Healthy Living Statistical Update on HIV/AIDS: January 1985-December 2007. 2008, Communicable Disease Control Branch, Public Health Division, Manitoba Health and Healthy Living.
12. Saskatchewan Health HIV/AIDS in Saskatchewan, 2007. 2008, Public Health Branch, Saskatchewan Health.
13. Poundstone KE, Strathdee SA, Celentano DD. The social epidemiology of human immunodeficiency virus/acquired immunodeficiency syndrome. Epidemiol Rev 2004, 26:22-35. 10.1093/epirev/mxh005, 15234945.
14. Luke DA. Getting the big picture in community science: methods that capture context. Am J Community Psychol 2005, 35:185-200. 10.1007/s10464-005-3397-z, 15909794.
15. Houck CD, Lescano CM, Brown LK. Islands of risk: subgroups of adolescents at risk for HIV. J Pediatr Psychol 2006, 31:619-29. 10.1093/jpepsy/jsj067, 16120764.
16. Zenilman JM, Ellish N, Fresia A, et al. The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Sex Trans Dis 1999, 26:75-81.
17. Steinman KJ, Hu Y. Substance use among American Indian Youth in an eastern city. J Ethn Subst Abuse 2007, 6:15-29. 10.1300/J233v06n01_02, 17430814.
18. Howard MO, Perron BE. A survey of inhalant use disorders among delinquent youth: prevalence, clinical features, and latent structure of DSM-IV diagnostic criteria. BMC Psychiatry 2009, 9(8). doi:10.1186/471-244X/9/8, 2657136, 19267939.
19. Howard MO, Walker RD, Walker PS, et al. Inhalant use among urban American Indian youth. Addiction 1999, 94:83-95. 10.1046/j.1360-0443.1999.941835.x, 10665100.
20. Wu LT, Howard MO. Is inhalant use a risk factor for heroin and injection drug use among adolescents in the United States. Addict Behav 2007, 32:265-81. 10.1016/j.addbeh.2006.03.043, 1828908, 16713124.
21. Spear S, Longshore D, Micarffrey D, et al. Prevalence of substance use among white and American Indian young adolescents in a Northern Plains state. J Psychoactive Drugs 2005, 37:1-6.
22. Dinwiddie SH. Abuse of inhalants: a review. Addiction 1994, 89:925-39. 10.1111/j.1360-0443.1994.tb03348.x, 7950851.
23. Beauvais F, Waymann JC, Jumper-Thurman P, et al. Inhalant abuse among American Indian, Mexican American, and Non-Latino White adolescents. Am J Drug Alcohol Abuse 2002, 28:171-87. 10.1081/ADA-120001287, 11853132.
24. Weir E. Inhalant use and addiction in Canada. CMAJ 2001, 164:397. 80757, 11232151.
25. Dell CA, Dell DE, Hopkins D. Resiliency and holistic inhalant abuse treatment. Journal of Aboriginal Health 2005, 2(1):4-13.
26. McGarvey EL, Clavet GJ, Mason W, et al. Adolescent inhalant abuse: environments of use. Am J Drug Alcohol Abuse 1999, 25:731-41. 10.1081/ADA-100101889, 10548445.
27. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national results on adolescent drug use: Overview of key findings, 2004 2005, Rockville, MD: National Institute on Drug Abuse.
28. Collin C. Substance abuse issues and public policy in Canada: IV. prevalence of use and its consequences. 2006, Ottawa, Canada: Library of Parliament.
29. Wu LT, Howard MO. Psychiatric disorders in inhalant users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alc Dep 2007, 88:146-55.
30. Wu LT, Pilowsky DJ, Schlenger WE. Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc 2004, 43:1206-14.
31. Marjot R, McLeod AA. Chronic Non-neurological Toxicity from Volatile Substance Abuse. Hum Exp Toxicol 1989, 8(4):301-6.
32. Williams JF, Storck M, , et al. and the Committee on Substance Abuse Inhalant Abuse. Pediatrics 2007, 119(5):1009-17. 10.1542/peds.2007-0470, 17473104, and the Committee on Substance Abuse.
33. Esmail A, Warburton B, Bland JM, et al. Regional variations in deaths from volatile solvent abuse in Great Britain. Addiction 1997, 92(12):1765-71. 10.1111/j.1360-0443.1997.tb02896.x, 9581008.
34. Collins D, Pan Z, Johnson K, et al. Individual and contextual predictors of inhalant use among 8th graders: a multilevel analysis. J Drug Educ 2008, 38(3):193-210. 10.2190/DE.38.3.a, 19157040.
35. Fendrich M, Mackesy-Amiti ME, Wislar JS, et al. Childhood abuse and the use of inhalants: differences by degree of use. Am J Public Health 1997, 87(5):765-9. 10.2105/AJPH.87.5.765, 1381047, 9184503.
36. Mackesy-Amiti ME, Fendrich M. Trends in Inhalant Use Among High School Students in Illinois: 1993-1995. Am J Drug Alcohol Abuse 2000, 26(4):569-91. 10.1081/ADA-100101896, 11097193.
37. Wu LT, Ringwalt CL. Inhalant use and disorders among adults in the United States. Drug Alc Dep 2006, 85(1):1-11.
38. Wu LT, Howard MO, Pilowsky DJ. Substance use disorders among inhalant users: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addict Behav 2008, 33(7):968-73. 10.1016/j.addbeh.2008.02.019, 2422848, 18403132.
39. Altenkirch H, Kindermann W. Inhalant abuse and heroin addiction: a comparative study in 574 opiate addicts with and without a history of sniffing. Addict Behav 1986, 11:93-104. 10.1016/0306-4603(86)90033-X, 3739809.
40. Bates SC, Plemons BW, Jumper-Thurman P, et al. Volatile solvent use: Patterns by gender and ethnicity among school attenders and dropouts. Drugs Soc 1997, 10(1/2):61-78.
41. Howard MO, Jenson JM. Inhalant use among antisocial youth:: prevalence and correlates. Addict Behav 1999, 24(1):59-74. 10.1016/S0306-4603(98)00039-2, 10189973.
42. Storr CL, Westergaard R, Anthony JC. Early onset inhalant use and risk for opiate initiation by young adulthood. Drug Alc Dep 2005, 78:253-61.
43. Johnson EO, Schutz CG, Anthony JC, et al. Inhalants to heroin: a prospective analysis from adolescence to adulthood. Drug Alc Dep 1995, 40:159-64.
44. Dinwiddie SH, Reich T, Cloninger CR. Solvent use as a precursor to intravenous drug abuse. Compr Psychiatry 1991, 32:133-40. 10.1016/0010-440X(91)90005-W, 2022112.
45. Howard MO, Jenson JM. Inhalant use among antisocial youth: prevalence and correlates. Addict Behav 1999, 24(1):59-74. 10.1016/S0306-4603(98)00039-2, 10189973.
46. Health Canada First Nations, Inuit and Aboriginal Health Treatment Centre Directory. 2010, (Accessed May 4 2010), Health Canada., http://www.hc-sc.gc.ca/fniah-spnia/substan/ads/nnadap-pnlaada_dir-rep-eng.php
47. D'Amanda C, Plumb M, Taintor Z. Heroin addicts with a history of glue sniffing: a deviant group within a deviant group. Int J Addict 1977, 12:255-70.
48. Wylie JL, Shah L, Jolly AM. Incorporating geographic settings into a social network analysis of injection drug use and bloodborne pathogen prevalence. Health Place 2006, 13:617-28. 10.1016/j.healthplace.2006.09.002, 17074527.
49. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006, 6:229. 10.1186/1471-2458-6-229, 1586015, 16970811.
50. Shaw SY, Shah L, Jolly AM, et al. Identifying heterogeneity among intravenous drug users: a cluster analysis approach. Am J Public Health 2008, 98:1430-7. 10.2105/AJPH.2007.120741, 18556614.
51. StataCorp Stata Statistical Software: Release 9. 2005, College Station: StataCorp LP, StataCorp.
52. Anand SS, Yusuf S, Jacobs R, et al. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). The Lancet 2001, 358(9288):1147-53.
53. Brownridge BA. Understanding the Elevated Risk of Partner Violence Against Aboriginal Women: A Comparison of Two Nationally Representative Surveys of Canada. Journal of Family Violence 2008, 23(5):353-67.
54. MacMillan HL, MacMillan AB, Offord DR, et al. Aboriginal health. CMAJ 1996, 155:1569-78. 1334995, 8956834.
55. Shaw SY, Shah L, Jolly AM, et al. Determinants of IDU syringe sharing: The relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction 2007, 102:1626-35. 10.1111/j.1360-0443.2007.01940.x, 17854339.
56. Des Jarlais DC. Reducing syringe sharing among injection drug users in Winnipeg: 81% success or 19% failure?. Addiction 2007, 102:1636. 10.1111/j.1360-0443.2007.01991.x, 17854340.
57. Des Jarlais DC, Perlis T, Arasteh K, et al. Reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr 2004, 35:158-66. 10.1097/00126334-200402010-00010, 14722449.
58. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:59-65. 10.1097/00002030-199708000-00001, 9110076.
59. Miller CL, Wood E, Spittal P, et al. The future face of coinfection: prevalence and incidence of HIV and Hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004, 36:743-9. 10.1097/00126334-200406010-00012, 15167294.
60. Raboud JM, Boily MC, Rajeswaran J, et al. The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study. J Urban Health 2003, 80:302-20.
61. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998, 113:75-80. 1307729, 9722812.
62. Kuller LH. Epidemiology is the study of "epidemics" and their prevention. AJE 1991, 134:1051-6.
63. Ginzler JA, Cochran BN, Domenech-Rodriguez M, et al. Sequential progression of substance use among homeless youth: an empirical investigation of the gateway theory. Subst Use Misuse 2003, 38:725-38. 10.1081/JA-120017391, 12747403.
64. Des Jarlais DC, Perlis T, Arasteh K, et al. "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr 2004, 35(2):158-66. 10.1097/00126334-200402010-00010, 14722449.
65. McPherson M, Smith-Lovin L, Cook JM. Birds of a Feather: Homophily in Social Networks. Annu Rev Sociol 2001, 27:415-44.
66. Lorenc JD. Inhalant abuse in the pediatric population: a persistent challenge. Cur Opin Pediatr 2003, 15:204-9.
67. Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alc Dep 2006, 82(Suppl I):S71-S9.
68. Torrens M, San L, Peri JM, et al. Cocaine abuse among heroin addicts in Spain. Drug Alc Dep 1991, 27:29-34.
69. Stenbacka M, Beck O, Leifman A, et al. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev 2007, 26:55-63. 10.1080/09595230601036994, 17364837.
70. Byrne A, Kirby B, Zibin T, et al. Psychiatric and neurological effects of chronic solvent abuse. Can J Psychiatry 1991, 36:735-8.
71. Muller AA, Muller GF. Inhalant abuse. J Emerg Nurs 2006, 32:447-8. 10.1016/j.jen.2006.05.018, 16997041.